These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31806567)

  • 1. Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency.
    Zhang Y; Baheti G; Chapdelaine H; Hofmann J; Rojavin M; Tortorici M; Haddad E
    Int Immunopharmacol; 2020 Apr; 81():106005. PubMed ID: 31806567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency.
    Rojavin MA; Chapdelaine H; Tortorici MA; Praus M; Baheti G; Zhang Y; Hofmann J; Labrosse R; Dicaire R; Haddad E
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):664-670. PubMed ID: 31814328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
    Wasserman RL; Melamed I; Nelson RP; Knutsen AP; Fasano MB; Stein MR; Rojavin MA; Church JA
    Clin Pharmacokinet; 2011 Jun; 50(6):405-14. PubMed ID: 21553933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency.
    Landersdorfer CB; Bexon M; Edelman J; Rojavin M; Kirkpatrick CM; Lu J; Pfister M; Sidhu J
    Postgrad Med; 2013 Nov; 125(6):53-61. PubMed ID: 24200761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency.
    Luo D; Baheti G; Tortorici MA; Hofmann J; Rojavin MA
    Clin Ther; 2020 Jan; 42(1):196-209.e5. PubMed ID: 31910997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
    Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
    J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.
    Li Z; Dumas T; Seth Berry N; McCoy B; Yel L
    Int Immunopharmacol; 2021 Nov; 100():108044. PubMed ID: 34601202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
    Li Z; McCoy B; Engl W; Yel L
    J Clin Immunol; 2021 Aug; 41(6):1331-1338. PubMed ID: 34036490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases.
    Navarro-Mora G; Alberti JJ; Mondou E; Vilardell D; Vicente Torres J; Ayguasanosa J; Páez A
    Int Immunopharmacol; 2022 Mar; 104():108472. PubMed ID: 35008008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.
    Anderson JT; Bonagura VR; Cowan J; Hsu C; Mustafa SS; Patel NC; Routes JM; Sriaroon P; Vinh DC; Hofmann JH; Praus M; Rojavin MA
    J Clin Immunol; 2021 Feb; 41(2):458-469. PubMed ID: 33409867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases.
    Dumas T; Berry NS; Wolfsegger M; Jolles S; McCoy B; Yel L
    Int Immunopharmacol; 2019 Jun; 71():404-410. PubMed ID: 30952104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study.
    Cowan J; Bonagura VR; Lugar PL; Maglione PJ; Patel NC; Vinh DC; Hofmann JH; Praus M; Rojavin MA
    J Clin Immunol; 2021 Jan; 41(1):66-75. PubMed ID: 33025378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
    Hagan JB; Fasano MB; Spector S; Wasserman RL; Melamed I; Rojavin MA; Zenker O; Orange JS
    J Clin Immunol; 2010 Sep; 30(5):734-45. PubMed ID: 20454851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
    Tortorici MA; Yuraszeck T; Cornblath D; Bril V; Hartung HP; Sobue G; Lewis RA; Merkies ISJ; Lawo JP; Praus M; Durn BL; Mielke O; Ma X; Jauslin P; Pfister M; van Schaik IN;
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):839-850. PubMed ID: 34085779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS).
    Vultaggio A; Azzari C; Ricci S; Martire B; Palladino V; Gallo V; Pecoraro A; Pignata C; Spadaro G; Graziani S; Moschese V; Trizzino A; Boggia GM; Matucci A
    J Clin Immunol; 2018 Jul; 38(5):602-609. PubMed ID: 29951948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world results with IgPro20 for hypo- or agammaglobulinemia in Japan.
    Imai K; Ishii T; Nonoyama S; Yasumi T; Kanegane H; Fukushima T; Matsumaru M; Akasaki T; Usui H
    Pediatr Int; 2022 Jan; 64(1):e15362. PubMed ID: 36151913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.